Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH2 domain-containing protein 6 (SH2D6) is a cytoplasmic adaptor protein characterized by its Src Homology 2 (SH2) domain[4][5]. This domain enables the protein to bind specifically to phosphorylated tyrosine residues on target peptides, thus participating in intracellular signaling cascades, particularly those downstream of cell surface receptor protein tyrosine kinases[1][3][4]. SH2 domain adaptor proteins are essential for mediating signal transduction, helping route information from receptors on the cell surface to downstream signaling elements within the cell[1][3][6]. SH2D6 shares similarity with other signaling adaptors, such as BLNK, but its precise physiological ligands, interaction partners, and biological functions remain incompletely characterized. Current evidence from gene databases links SH2D6 only to rare genetic disorders through gene association, with no established therapeutic target status and no interacting drugs or known safety, biomarker, or mechanism-of-action profiles[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH2 domain-containing protein 6 (SH2D6).